Literature DB >> 33375121

CD85k Contributes to Regulatory T Cell Function in Chronic Viral Infections.

Anna Estrada Brull1, Felix Rost1, Josua Oderbolz2, Florian R Kirchner1,3, Salomé Leibundgut-Landmann1,3, Annette Oxenius2, Nicole Joller1.   

Abstract

Regulatory T cells (Tregs) prevent excessive immune responses and limit immune pathology upon infections. To fulfill this role in different immune environments elicited by different types of pathogens, Tregs undergo functional specialization into distinct subsets. During acute type 1 immune responses, type 1 Tregs are induced and recruited to the site of ongoing Th1 responses to efficiently control Th1 responses. However, whether a similar specialization process also takes place following chronic infections is still unknown. In this study, we investigated Treg specialization in persistent viral infections using lymphocytic choriomeningitis virus (LCMV) and murine cytomegalovirus (MCMV) infection as models for chronic and latent infections, respectively. We identify CD85k as a Th1-specific co-inhibitory receptor with sustained expression in persistent viral infections and show that recombinant CD85k inhibits LCMV-specific effector T cells. Furthermore, expression of the CD85k ligand ALCAM is induced on LCMV-specific and exhausted T cells during chronic LCMV infection. Finally, we demonstrate that type 1 Tregs arising during chronic LCMV infection suppress Th1 effector cells in an ALCAM-dependent manner. These results extend the current knowledge of Treg specialization from acute to persistent viral infections and reveal an important functional role of CD85k in Treg-mediated suppression of type 1 immunity.

Entities:  

Keywords:  ALCAM; CD85k; chronic viral infection; regulatory T cells

Year:  2020        PMID: 33375121     DOI: 10.3390/ijms22010031

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  1 in total

Review 1.  Dampening antiviral immunity can protect the host.

Authors:  Camilla Panetti; Kung-Chi Kao; Nicole Joller
Journal:  FEBS J       Date:  2021-02-23       Impact factor: 5.622

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.